

2021 Independent Medical Education Call for Grant Notification

Issue Date: **November 5, 2021**

The *Independent Medical Education team at Genentech, a member of the Roche Group*, invites accredited educational providers to submit applications for independent, certified medical education grants subject to the terms described below. This Call for Grants Notification (CGN) provides public notice of the availability of funds in a general topic area for activities for which recognized scientific or educational needs exist and funding is available.

Purpose: As part of Genentech's scientific mission, Genentech supports grants for independent medical education that aim to improve patient care by focusing on the improved application of knowledge, competence, and performance among healthcare professionals. This mission is achieved by supporting quality independent education that addresses evidence-based, bona fide educational gaps in accordance with the ACCME, AMA, PhRMA Code, OIG and FDA guidance.

Notification: Genentech CGNs are made available through our online Genentech Funding Request System (gFRS) site (<http://funding.gene.com>) along with the websites for the Alliance for Continuing Education in the Health Professions (ACEhp) and the Society for Academic Continuing Medical Education (SACME). In addition, an email is distributed to all registered gFRS users who have previously applied for support of an independent education activity. *There have been no predetermined approvals, nor any identified preferred educational providers. All submissions will be reviewed equally and thoroughly.*

Terms and Conditions

1. All grant applications received in response to this CGN will be reviewed in accordance with all Genentech policies and policy guidelines. (Please refer to the publicly available criteria on <http://funding.gene.com>)
2. This CGN does not commit Genentech to award a grant or pay any costs incurred in the preparation of a response to this request.
3. Genentech reserves the right to approve or deny any or all applications received as a result of this request or to cancel, in part or in its entirety, this CGN.
4. For compliance reasons, and in fairness to all providers, all communications about this CGN must come exclusively to Genentech's department of Medical Education and Research Grants. Failure to comply will automatically disqualify providers.
5. Failure to follow the instructions within this CGN may result in a denial.

Instructions

Eligibility Criteria	<ul style="list-style-type: none">• U.S. based education provider• Registered account in gFRS• Accredited to provide CME/CE and in good standing (e.g. ACCME, ANCC, ACPE, etc.)
Geographical Scope	<ul style="list-style-type: none">• Educational initiatives must be U.S.-based only

Submission Directions	Application Process	Deadlines
Step 1	Providers who meet the eligibility criteria and are interested in submitting a response to this CGN will have 3 weeks to complete a full grant proposal through funding.gene.com. When submitting the application, please be sure to: Select the Therapeutic Area (Oncology), and Disease State (Lymphoma Diffuse Large B-Cell) Include “CGN November 2021 [Insert Program Title]” in the program title of the grant	November 30, 2021
Step 2	Grant decisions will be made by Genentech within 1 week of November 30th, 2021, and decision notifications will be issued to the accredited educational provider through our grant platform as per usual	December 7, 2021
Step 3	Funded Project Start Date: within 8 weeks of grant award	February 2022

Additional Considerations

Provider(s) who are awarded grants are encouraged but not required to:

1. Demonstrate key findings via outcomes analysis and report the extent to which the education met the stated objectives and other key findings.
2. Describe how learners demonstrated competence, performance, or patient outcomes improvement as a result of the educational activity.
3. Summarize (through written analysis) the provider’s understanding and interpretation of the outcomes data and identify any persistent educational gaps, unanticipated barriers and/or activity/outcomes limitations.

Currently Available CGN Focus Area(s):

Focus	Opportunity
<p>Therapeutic Area:</p> <p>Oncology</p> <p>Disease:</p> <p>Diffuse large B-cell lymphoma</p> <p>Learning Audience:</p> <p>Hematologist</p> <p>Hematologist-Oncologist</p> <p>Community Oncologist</p> <p>Nurses</p> <p>Pharmacists</p> <p>Patients (optional)</p> <p>Support Available:</p> <p>Up to \$300,000</p> <p>Knowledge- and Competence-based Emerging Education (<i>Understanding & Addressing national or local gaps</i>)</p>	<p>Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma, representing 25% of all lymphoproliferative disorders. Despite its aggressive disease course, approximately 50% to 70% of patients may be cured by current standard of care consisting of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy. Nevertheless, R-CHOP is found to be inadequate in 30% to 40% of patients, with a 10-year overall survival (OS) rate of approximately 43.5% for patients with stage II-IV DLBCL receiving R-CHOP alone.</p> <p>It is important for healthcare professionals to understand the unmet medical need for certain patients in the frontline treatment of DLBCL, the potential impact of the risk of disease progression for patients, the potential cost of therapy failure in the frontline, and potential new approaches in treating these patients.</p> <p>Genentech recognizes the need to support independent education to help educate about the unmet need of certain patients diagnosed with DLBCL.</p> <p>References:</p> <ol style="list-style-type: none"> 1. Coiffier, Bertrand, and Clémentine Sarkozy. "Diffuse large B-cell lymphoma: R-CHOP failure-what to do?." Hematology. American Society of Hematology. Education Program vol. 2016,1 (2016): 366-378. doi:10.1182/asheducation-2016.1.366 2. Lymphoma Research Foundation. Understanding Diffuse Large B-Cell Lymphoma. Website. https://lymphoma.org/wp-content/uploads/2018/05/LRF_FACTSHEET_DIFFUSE_LRG_BCELL_LYMPHOMA_DLBCL.pdf. Accessed Oct 8, 2021 . 3. Syed YA, Jiang C, Switchenko J, et al. Improved progression-free survival for bulky and nonbulky advanced stage diffuse large B-cell lymphoma with consolidative radiation therapy: a bi-institutional analysis. Cureus. Published online August 11, 2021. doi:10.7759/cureus.17107 4. National Comprehensive Cancer Network (NCCN). NCCN Guidelines Version 5.2021 Diffuse Large B-Cell Lymphoma. Website. Accessed October 7, 2021. https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf